Arvelle Therapeutics
Manufacturing · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Zählerweg 6, Zug, Zug, 6300, SwitzerlandPhone Number
(888) 317-1041Website
www.arvelletx.comRevenue
$19.7 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Arvelle Therapeutics
Founded in 2019, Arvelle Therapeutics is a company that specializes in the development and commercialization of carbamate, an investigational anti-seizure medication. Arvelle Therapeutics is located in Switzerland.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arvelle Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Arvelle Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Arvelle Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Arvelle Therapeutics
Earning: See what the market has to say on Arvelle Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Arvelle Therapeutics has new funding data
Product Launch: Get notified when Arvelle Therapeutics launches new products
Check out if Arvelle Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Arvelle Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Arvelle Therapeutics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Arvelle Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Arvelle Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Arvelle Therapeutics.
Arvelle Therapeutics financials insights
Gather financial insights about Arvelle Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$207.8M
Arvelle Therapeutics Tech Stack
A closer look at the technologies used by Arvelle Therapeutics
See more technologies
Most Recent Scoops
New Hire
Management Move
Ella Izquierdo has been named Director, Marketing UK (Ireland). Previously, Izquierdo served as Senior Brand Manager, International At Intercept Pharmaceutical Ltd (Europe) at Intercept Pharmaceuticals.
Mergers & Acquisitions (M&A)
Promotion
Executive Move
Mark Altmeyer has been promoted to the role of President & Chief Executive Officer.
Funding
Arvelle Therapeutics News & Media
Angelini Pharma Acquires Arvelle Therapeutics, for Up To $960M
Angelini Pharma, a Rome, Italy-based international pharmaceutical company which is a part of the private Italian Angelini Group, acquired Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders. Under the definitive merger agreement, Angelini Pharma will acquire Arvelle Therapeutics in an all cash transaction for a total […] The post Angelini Pharma Acquires Arvelle Therapeutics, for Up To $960M appeared firAngelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments
ROME, Jan. 4, 2021 /PRNewswire/ -- Angelini Pharma, an international pharmaceutical company which is a part of the private Italian Angelini Group – and Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS...Cenobamate Designated Promising Innovative Medicine (PIM) by the UK’s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults
PIM designation is an early indication that cenobamate is a promising candidate for the MHRA’s Early Access to Medicine Scheme
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arvelle Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2019, Arvelle Therapeutics is a company that specializes in the development and commercialization of carbamate, an investigational anti-seizure medication. Arvelle Therapeutics is located in Switzerland.... Read More
